Medical Device Regulation in China
The National Medical Products Administration (NMPA) regulates medical devices under the 2021 Regulations on Supervision and Administration of Medical Devices. China uses a three-class risk system. Foreign manufacturers must appoint a Chinese Authorized Agent. Registration timelines for novel Class III devices can exceed 2 years.
Device Classification
Class I (low risk): filing (Beian) at local authority — e.g., elastic bandages, forceps. Class II (moderate risk): registration at provincial NMPA — e.g., ventilators, diagnostic reagents. Class III (high risk): registration at national NMPA — e.g., implantable devices, cardiac catheters. Strictest technical review at national level.
Official classification guidance →Standards & Key Principles
Applicable Standards
Key Principles
- Mandatory local Authorized Agent (境内代理人) for foreign manufacturers
- All documentation must be in Simplified Chinese
- Clinical evaluation: literature review or China-specific clinical trial often required
- Production QMS inspection by NMPA
- UDI implementation mandatory (phased since 2022)
- Registration validity: 5 years, with re-registration required
Pre-Market Requirements
Self-declaration filing with local market supervision administration. No pre-market technical review by NMPA.
Technical dossier including product description, standards compliance, testing reports, QMS, labeling, and clinical evaluation.
Full dossier submitted to national NMPA via CMDE: clinical evaluation (literature or trial), QMS inspection, technical review. Typical timeline: 24–36+ months for novel devices.
Foreign manufacturers without a Chinese entity must appoint a Chinese Authorized Agent jointly responsible for compliance.
Post-Market Requirements
Manufacturers must submit annual product quality self-inspection reports to NMPA.
Deaths/near-death events within 15 days; other serious events within 30 days. Reporting via China's National ADR Monitoring Center.
Device registrations valid for 5 years; re-registration application required 6 months before expiry.
International Recognition & Reliance
China generally does not accept foreign approvals as substitutes for NMPA registration. FDA/CE data may be submitted as supporting evidence but China-specific data is usually also required.